# Eric Delbridge

> Eric Delbridge, MD is a General Partner at Sofinnova Investments in Menlo Park, California, where he architects the firm's BioEquities strategy - a $1.5B public equity fund focused on global therapeutics companies. An unusual combination of physician, Wharton MBA (Palmer Scholar), and Yale Classics graduate, Delbridge brings over a decade of hedge fund investing experience from Balyasny Asset Management and Spring Point Capital, plus prior investment banking work at Lazard and Credit Suisse. He joined Sofinnova in 2016 and was elevated to General Partner in 2019, helping steward a firm with $3.7B under management, 118 companies funded, 55 IPOs, and 30 acquisitions.

- **Role:** General Partner at Sofinnova Investments
- **Organizations:** Sofinnova Investments, Balyasny Asset Management, Spring Point Capital, Lazard, Credit Suisse
- **Nationality:** American
- **Education:** B.A. in Classics (cum laude), Yale University, M.D., Northwestern University, M.B.A., The Wharton School, University of Pennsylvania
- **Known for:** Palmer Scholar at The Wharton School, University of Pennsylvania, Robert D. Eilers Memorial Award for achievement in community service, Built and leads the Sofinnova BioEquities strategy - a $1.5B public equity fund

## Career timeline

- **Early career** — Healthcare Investment Banker at Credit Suisse, focused on biotech M&A
- **Mid career** — Healthcare Investment Banker at Lazard, focused on biotech M&A
- **~2008-2013** — Partner at Spring Point Capital (formerly Botti Brown Asset Management), long/short equity healthcare
- **~2013-2016** — Managed market neutral therapeutics and healthcare portfolios at Balyasny Asset Management
- **2016** — Joined Sofinnova Investments as Portfolio Manager, developing the BioEquities strategy
- **2019** — Promoted to General Partner at Sofinnova Investments

## Achievements

- Palmer Scholar at The Wharton School, University of Pennsylvania
- Robert D. Eilers Memorial Award for achievement in community service
- Built and leads the Sofinnova BioEquities strategy - a $1.5B public equity fund
- Helped Sofinnova grow assets under management to $3.7B
- Over 10 years of hedge fund investing experience in healthcare and therapeutics
- Graduated cum laude from Yale University with a B.A. in Classics

## Latest updates

- **2025-11** — Sofinnova Investments raised latest funding round, with $755M+ in latest raise and $2.8B+ total funding
- **2025-05** — Sofinnova BioEquities, LP filed most recent fund raising round in equity

## Links

- Website: https://sofinnova.com
- LinkedIn: http://www.linkedin.com/in/eric-delbridge-72304320

---

Profile page: https://yespress.io/eric-delbridge
Published by YesPress — https://yespress.io
Last updated: 2026-05-19